<DOC>
	<DOCNO>NCT02363491</DOCNO>
	<brief_summary>The dose-confirming part study , comprise least 10 patient design single center , prospective , single arm , open label patient fail unresponsive Azacitidine ( AZA ) Decitabine ( may also additionally fail Erythropoiesis Stimulating Agent ( ESA ) follow dose expansion part additional 30 patient ; objective whole study ass safety , efficacy , pharmacokinetics pharmacodynamics intravenously infuse multiple dos OPN-305 low intermediate-1 risk myelodysplastic syndrome ( Second line Lower risk MDS ) .</brief_summary>
	<brief_title>A Phase I/II Study OPN-305 Second-line Lower Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Written inform consent Age ≥ 18 year Diagnosis MDS ( de novo secondary ) bone marrow biopsy base World Health Organization ( WHO ) classification Low Intermediate1 risk category MDS use IPSS ( International Prognostic Scoring System ) Not respond fail treatment AZA decitabine ( note also eligible additionally fail another ESA least 4 cycle ) Responders cease respond Never respond Red Blood cell transfusion dependent ( define ≥ 2 RBC unit require 8 week prior start study ) . Life expectancy ≥ 3 month ECOG performance status Grade 02 Serum bilirubin level ≤2 x ULN Serum ALT AST level ≤2.5 x ULN Creatinine clearance &gt; 50 ml/min calculate CockcroftGault formula Negative urine βhuman chorionic gonadotropin ( βHCG ) pregnancy test fertile woman screen confirm serum pregnancy test 48 hour prior OPN305 administration If sexually active female , patient must be/have one following : Postmenopausal define absence menses least one year ( serum FSH ≥20IU/L also measure accord local practice ) , OR Surgically sterile define bilateral tubal ligation least 6 month prior administration study drug , bilateral oophorectomy , complete hysterectomy , OR Using effective mean contraception plan continue duration treatment 3 month . If sexually active male , patient must : Agree use effective mean contraception ( per sitespecific guideline ) plan continue 6 month last dose OPN305 . Agree donate sperm 6 month last dose OPN305 Diagnosis MDS bone marrow biopsy Intermediate2 High risk category MDS base WHO classification use IPSS ( International Prognostic Scoring System ) Patients 5q del MDS unless fail Revlimid ( lenalidomide ) Prior history acute leukemia AML Unable/unwilling undergo bone marrow sample Prior history bone marrow transplantation Prior malignancy ( noninvasive malignancy include situ cervical cancer , Bowen 's disease basal cell cancer skin ) unless treat curative intent without evidence disease 3 year randomization Active viral bacterial infection : include infection actively treat even sign symptom appear resolve . Courses antibiotic antiviral treatment complete patient enrol Unstable angina , congestive heart failure [ NYHA ( New York Heart Association ) &gt; class II ] , uncontrolled hypertension [ diastolic &gt; 100 mmHg ] , uncontrolled cardiac arrhythmia , recent ( within 1 year ) myocardial infarction , uncontrolled diabetes mellitus Clinical Evidence CNS disease Less 4 week since therapy MDS Prior history anaphylaxis product type History presence medical condition disease substance abuse investigator 's assessment would place patient unacceptable risk study participation Lactating pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>